{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:36:25Z","timestamp":1792787785062,"version":"4.5.0"},"reference-count":29,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["2016-I2M-1-013"],"award-info":[{"award-number":["2016-I2M-1-013"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2019-I2M-2-005"],"award-info":[{"award-number":["2019-I2M-2-005"]}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2017ZX10201302-009"],"award-info":[{"award-number":["2017ZX10201302-009"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2021,11,1]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Enlarging tuberculosis (TB) preventive treatment among at-risk populations is a critical component of the End TB Strategy. There is an urgent need to develop suitable latent tuberculosis infection (LTBI) testing and treatment tools according to the local TB epidemic and available resources worldwide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Based on an open-label randomised controlled trial conducted since 2015 in China among rural residents aged 50\u201370\u2005years with LTBI, the protective efficacy of a 6-week twice-weekly regimen of rifapentine plus isoniazid was further evaluated in a 5-year follow-up survey.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      1298 treated participants and 1151 untreated controls were included in the 5-year protective efficacy analysis. In the per-protocol analysis, the incidence rate was 0.49 (95% CI 0.30\u20130.67) per 100 person-years in the untreated control group and 0.19 (95% CI 0.07\u20130.32) per 100 person-years in the treated group; the protection rate was 61.22%. Subgroup analysis showed that the protection rate was 76.82% in the per-protocol analysis among participants with baseline interferon (IFN)-\u03b3 levels in the highest quartile (\u22653.25\u2005IU\u00b7mL\n                      <jats:sup>\u22121<\/jats:sup>\n                      ). Multiple logistic regression analysis indicated that participants with baseline body mass index &lt;18.5\u2005kg\u00b7m\n                      <jats:sup>\u22122<\/jats:sup>\n                      and with pulmonary fibrotic lesions had increased hazard of developing active disease with an adjusted hazard ratio (aHR) of 3.64 (95% CI 1.20\u201311.00) and 5.99 (95% CI 2.20\u201316.27), respectively. In addition, individuals with higher baseline IFN-\u03b3 levels showed an increased risk of TB occurrence (aHR 2.27, 95% CI 1.13\u20134.58).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest the 6-week twice-weekly regimen of rifapentine plus isoniazid for LTBI treatment might be an optional tool for TB control in the Chinese population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.02359-2021","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T12:10:25Z","timestamp":1636632625000},"page":"2102359","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Protective efficacy of 6-week regimen for latent tuberculosis infection treatment in rural China: 5-year follow-up of a randomised controlled trial"],"prefix":"10.1183","volume":"60","author":[{"given":"Henan","family":"Xin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boxuan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dakuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zisen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueling","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaoxia","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongpeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhusheng","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouguo","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"key":"2024102102452113000_60.1.2102359.1","unstructured":"World Health Organization . Global tuberculosis report 2020. 2020. www.who.int\/publications\/i\/item\/9789240013131 Date last accessed: 24 December 2020."},{"key":"2024102102452113000_60.1.2102359.2","first-page":"889","article-title":"Update on latent tuberculosis infection","volume":"89","author":"Hartman-Adams","year":"2014","journal-title":"Am Fam Physician"},{"key":"2024102102452113000_60.1.2102359.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1405427"},{"key":"2024102102452113000_60.1.2102359.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60570-0"},{"key":"2024102102452113000_60.1.2102359.5","unstructured":"World Health Organization . Implementing the End TB Strategy: the essentials. 2015. www.who.int\/tb\/publications\/2015\/end_tb_essential.pdf Date last accessed: 24 December 2020."},{"key":"2024102102452113000_60.1.2102359.6","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00214014"},{"key":"2024102102452113000_60.1.2102359.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104875"},{"key":"2024102102452113000_60.1.2102359.8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","article-title":"Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid","volume":"169","author":"Villarino","year":"2015","journal-title":"JAMA Pediatr"},{"key":"2024102102452113000_60.1.2102359.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806808"},{"key":"2024102102452113000_60.1.2102359.10","doi-asserted-by":"crossref","unstructured":"World Health Organization . WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. 2020. www.who.int\/publications-detail\/who-consolidated-guidelines-on-tuberculosis-module-1-prevention-tuberculosis-preventive-treatment Date last accessed: 24 March 2020.","DOI":"10.30978\/TB2021-2-86"},{"key":"2024102102452113000_60.1.2102359.11","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1473-3099(17)30402-4","article-title":"Incidence of active tuberculosis among individuals with latent tuberculosis infection in rural China: follow-up results of a population-based multicenter prospective cohort study","volume":"17","author":"Gao","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2024102102452113000_60.1.2102359.12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01470-2018"},{"key":"2024102102452113000_60.1.2102359.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)71085-0"},{"key":"2024102102452113000_60.1.2102359.14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00235-2016"},{"key":"2024102102452113000_60.1.2102359.15","first-page":"827","article-title":"Isoniazid prophylaxis among Alaskan Eskimos: a final report of the Bethel isoniazid studies","volume":"119","author":"Comstock","year":"1979","journal-title":"Am Rev Respir Dis"},{"key":"2024102102452113000_60.1.2102359.16","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02048-2019"},{"key":"2024102102452113000_60.1.2102359.17","first-page":"947","article-title":"5-year follow-up of active tuberculosis development from latent infection in rural China","volume":"70","author":"Xin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024102102452113000_60.1.2102359.18","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-211147"},{"key":"2024102102452113000_60.1.2102359.19","doi-asserted-by":"crossref","first-page":"1555.e1","DOI":"10.1016\/j.cmi.2020.02.009","article-title":"Dynamic changes of interferon gamma release assay results with latent tuberculosis infection treatment","volume":"26","author":"Xin","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2024102102452113000_60.1.2102359.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30355-4"},{"key":"2024102102452113000_60.1.2102359.21","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.5588\/ijtld.16.0880","article-title":"Interferon-gamma response to the treatment of active pulmonary and extra-pulmonary tuberculosis","volume":"21","author":"Liang","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102102452113000_60.1.2102359.22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008257"},{"key":"2024102102452113000_60.1.2102359.23","first-page":"5","article-title":"[The incidence rate of active pulmonary tuberculosis among adult population with fibrotic lesions.]","volume":"78","author":"Shimouchi","year":"2003","journal-title":"Kekkaku"},{"key":"2024102102452113000_60.1.2102359.24","first-page":"286","article-title":"The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals","volume":"8","author":"Cegielski","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102102452113000_60.1.2102359.25","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.12.1297"},{"key":"2024102102452113000_60.1.2102359.26","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyp308"},{"key":"2024102102452113000_60.1.2102359.27","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kws007"},{"key":"2024102102452113000_60.1.2102359.28","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/ijo.2017.64","article-title":"Obesity\/overweight reduces the risk of active tuberculosis: a nationwide population-based cohort study in Taiwan","volume":"41","author":"Yen","year":"2017","journal-title":"Int J Obes"},{"key":"2024102102452113000_60.1.2102359.29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050152"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.02359-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:52:34Z","timestamp":1740358354000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.02359-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,11]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,7,7]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1183\/13993003.02359-2021"],"URL":"https:\/\/doi.org\/10.1183\/13993003.02359-2021","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,11]]}}}